Neoadjuvant Cabo + Nivo in locally advanced HCC | EXEL Message Board Posts


EXEL   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  27805 of 28050  at  7/29/2021 2:57:30 PM  by

SirCharlesMartin

The following message was updated on 7/29/2021 3:01:15 PM.

Neoadjuvant Cabo + Nivo in locally advanced HCC

A potentially curative hepatic resection is the optimal treatment for hepatocellular carcinoma (HCC) but most patients are not candidates for resection and most resected HCCs eventually recur. Until recently, neoadjuvant systemic therapy for HCC has been limited by a lack of effective systemic agents. Here, in a single-arm phase 1b study, we evaluated the feasibility of neoadjuvant cabozantinib and nivolumab in patients with HCC, including patients outside of traditional resection criteria (ClinicalTrials. gov ID NCT03299946). Of 15 patients enrolled, 12 (80%) underwent successful margin-negative resection and 5 out of 12 (42%) had major pathological responses. In-depth biospecimen profiling demonstrated an enrichment in effector T cells, as well as tertiary lymphoid structures, CD138+ plasma cells, and a distinct spatial arrangement of B cells in responders compared to nonresponders, indicating an orchestrated B cell contribution to antitumor immunity in HCC. 
 
https://www.nature.com/articles/s43018-021-00234-4
 
Little twitter thread as well:
https://twitter.com/MarkYarchoan/status/1420808413869592579 
 


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 7  
   Views: 0 []
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board


Financial Market Data provided by
.
Loading...